Brainstorm Cell Therapeutics

" BrainStorm Cell Therapeutics Ralph Kern MD MHSc. Chief Operating Officer and Chief Medical Officer September 2018 NASDAQ: BCLI March 22, 2018 " Forward Looking Statement Statements in this announcement other than historical data and information constitute "forward-looking statements" and involve risks and uncertainties that could cause BrainStorm Cell Therapeutics Inc.'s actual results to differ materially from those stated or implied by such forward-looking statements. Terms and phrases such as "may", "should", "would", "could", "will", "expect", "likely", "believe", "plan", "estimate", "predict", "potential", and similar terms and phrases are intended to identify these forward-looking statements. The potential risks and uncertainties include, without limitation, risks associated with BrainStorm's limited operating history, history of losses; minimal working capital, dependence on its license to Ramot's technology; ability to adequately protect the technology; dependence on key executives and on its scientific consultants; ability to obtain required regulatory approvals; and other factors detailed in BrainStorm's annual report on Form 10-K and quarterly reports on Form 10-Q available at

These factors should be considered carefully, and readers should not place undue reliance on BrainStorm's forward-looking statements. The forward-looking statements contained in this press release are based on the beliefs, expectations and opinions of management as of the date of this press release. We do not assume any obligation to update forward-looking statements to reflect actual results or assumptions if circumstances or management's beliefs, expectations or opinions should change, unless otherwise required by law. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. 2 " Manufacturing Excellence NurOwn Cryopreservation Manufacturing Capabilities Strong Science Cell and Disease biology Industry CNS experience Strategic Partnerships California Institute for Regenerative Medicine (CIRM) Patient Focus

Patient Advocacy Leadership 3 " Amyotrophic Lateral Sclerosis (ALS) Parkinsons Progressive Disease Multiple (PD) Sclerosis (MS) Alzheimers Disease (AD) Huntingtons Autism Spectrum Disease (HD) Disorder (ASD)

Global patients US patients Clinical study endpoints 220,000 10,000,000 1,250,000 47,000,000 300,000 35,000,000 30,000 1,000,000 500,000 5,000,000


CSF MCP-1 CSF CHIT-1 CSF NfL Dopamine transporter imaging (DAT EMA approved July 27, 2018) MRI CSF sCD27 CSF CHIT-1 CSF NfL CSF Tau CSF AB-42 CSF NfL PET CSF NfL CSF Tau

CSF mHTT CSF BDNF CSF MCP-1 " 5 " Nature Communications, 2016. " Nature Communications, 2016. " 8 " CD73

M SC-NTF M SC CD44 PBMC only CD markers PBMC co-cultured with MSC-NTF T regulatory cells (Tregs) CD3 M SC VEGF CD14 CD19

" Repeat dosing Rapid progressors # of Study Participants 26 Phase... 200 48 Pha Pha 10 " Screening (V1)

BMA (V4) Transplantation (V5)* End of Study (V10) -12-16 weeks -3-5 weeks 0 24-36 weeks (~ 3 months) CSF Collection (V5 and V6) Study Design N=48 participants (16 per site)

Randomized 3:1 Blinded to allocation (~ 9-10 months) No deaths or treatment related SAEs No drop outs related to SAEs Most common adverse events transient and mild/moderate severity and procedure related Efficacy ALSFRS-R SVC *IT 125M cells/4 ml and IM (R biceps and R triceps) BMA: Bone Marrow Aspirations Monthly visits 11 " Identifier: NCT03280056 12 " NurOwn ALS Phase 3 Study Sites Mayo Clinic (Rochester, MN) MGH (Boston, MA) California Pacific Medical Center, (San Francisco, CA) UMass (Worchester, MA) Cedar Sinai (Los Angeles, CA) UC Irvine

(Los Angeles, CA) 13 " NurOwn ALS Phase 3 Study Timeline Identifier: NCT03280056 * Supported by $16M CIRM CLIN-2 grant " Patent Name/ Int. App. No. ISOLATED CELLS AND POPULATIONS COMPRISING SAME FOR THE TREATMENT OF CNS DISEASES/PCT/IL2006/000699 Pending Jurisdictions Allowed Jurisdictions

US Hong Kong MESENCHYMAL STEM CELLS FOR THE TREATMENT OF CNS DISEASES PCT/ IL2009/000525 Granted Jurisdictions Expiry Date Europe, US 2030 US, Europe, Israel 2032 US, Japan 2038

METHODS OF GENERATING MESENCHYMAL STEM CELLS WHICH SECRETE NEUROTROPHIC FACTORS / PCT/IL2013/050660 Europe, Hong Kong, Israel, Canada, Brazil, Japan METHOD OF QUALIFYING CELLS /PCT IL2015/050159 US, Europe, Hong Kong, Israel, Canada, Brazil, Japan 2040 PCT 2042 Methods of treating ALS PCT/IL2017/050801 15

15 " BrainStorm Cell Therapeutics Prepared NASDAQ: BCLI Thank You! March 22, 2018

Recently Viewed Presentations

  • Project Management Tools: -

    Project Management Tools: -

    A work management system that is favored by Agile/Scrum users. Japanese for "visual signal." What are the main ideas? Three Columns: To Do, In Flight, Done. PULLING tasks vs. assigning tasks. A Kanban Board makes work/progress visual . What can...
  • Recognition Awards For Commitment to Battling Islamophobia Houria

    Recognition Awards For Commitment to Battling Islamophobia Houria

    - This award is in recognition of Houria's tireless and uncompromising challenge to us all (from individuals to nation states): to decolonise. Veterans for Peace - A not-for-profit NGO established in the UK by veterans of wars including those in...
  • Environmental and SWOT Analysis for Best Buy Co., Inc.

    Environmental and SWOT Analysis for Best Buy Co., Inc.

    Macro- and Micro-Environmental Analysis. ... The company's Environmental and SWOT analysis shows where the company is compared to it's external information and how and where the company can go ahead in the future. ... Environmental and SWOT Analysis for Best...
  • Le Subjonctif Le placement des pronoms 1. Emily

    Le Subjonctif Le placement des pronoms 1. Emily

    1. Emily prend des photos à Port Moody. 2. Erin et Alexis dessinent des dessins. 3. Hajer a demandé la question à toi. 4. Parsa chante les chansons en classe.
  • The value of flexibility - Department of Engineering ...

    The value of flexibility - Department of Engineering ...

    The Value of Phasing Stefan Scholtes Judge Institute of Management University of Cambridge MPhil Course 2004-05 Course content Introduction The forecast is always wrong The industry valuation standard: Net Present Value Sensitivity analysis The system value is a shape Value...
  • Best Practices in Budget Development

    Best Practices in Budget Development

    You may budget mileage at a rate higher than the federal reimbursement rate (which is $.58/mile as of 1/1/19), if that follows your organization's policy. If so, make a note in the budget narrative.
  • Texas Legislative History and Statutory Construction

    Texas Legislative History and Statutory Construction

    Pick the correct answer- All the problems in statutory interpretation in Texas stems from: The Legislature-because they can't write clear laws . The Judiciary-because the look for statutory problems where none in fact exist; or. Lawyers-because they inappropriately use statutory...
  • Introduction to Leddy Library -

    Introduction to Leddy Library -

    Introduction to Leddy Library. Welcome to UWindsor and Leddy Library! ... The Reference Help Desk helps you with your research needs and can help you use the library, find material, refine searches so that you find more items on your...